HEALTH

Amazon reportedly launches private-label OTC brand

BY DSN STAFF

An online giant has expanded into a new private-label category.

With no fanfare, Amazon in August launched an exclusive line of over-the-counter health products produced by private-label manufacturer Perrigo, CNBC reported. The Basic Care line, which includes 60 products that range from ibuprofen to hair regrowth treatment, could spark a price war and put pressure on store-brand profit margins, according to the report.

Amazon already sells branded OTC medications, and item from Perrigo’s generic GoodSense brand. While these products are all subject to the fluctuating prices from competitors, Amazon controls pricing of its Basic Care line, CNBC said. The Basic Care line includes 60 products, ranging from ibuprofen to hair regrowth treatment.

To read more, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

GSK presents child efficacy data supporting Fluarix Quadrivalent

BY Michael Johnsen

GSK presented today at the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices meeting that its Fluarix Quadrivalent vaccine demonstrated 63.2% efficacy against moderate to severe influenza and 49.8% efficacy against influenza of any severity in children 6 months through 35 months of age.

These results are based on a randomized, observer-blind, non-influenza vaccine-controlled trial that enrolled 12,018 children in five independent cohorts in 13 countries in Asia, Europe, and Central America from 2011 through the end of 2014.

“Children 6 months through 35 months of age are particularly vulnerable to the flu, and the efficacy results from this trial are promising,” Leonard Friedland, vice president, scientific affairs and public health, GSK Vaccines, said. “Fluarix Quadrivalent can help ensure health care provider and parents have the ability to help protect young children against the flu.”

Fluarix Quadrivalent was immunogenic against all four vaccine strains (i.e., A/H1N1, A/H3N2, B/Victoria and B/Yamagata).

The safety and reactogenicity profile was similar to vaccines used in the same age group. No safety signal was observed.

Additionally, the study found that Fluarix Quadrivalent reduced healthcare utilization (i.e., antibiotic use, general practitioner visits and emergency department visits) related to confirmed influenza illness.

Fluarix Quadrivalent was first approved in 2012 in the U.S. for the prevention of influenza disease in people 3 years of age and older. In 2018, the indication was expanded to children 6 months and older. It is also approved in more than 30 other countries worldwide.

Fluarix Quadrivalent is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluarix Quadrivalent is approved for use in persons aged 6 months and older.

There are two main types of seasonal flu viruses, A and B, that spread between people and can cause mild to severe illness. Most flu activity in the U.S. occurs from October through May, and it usually peaks between December and February.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

MainPointe Pharma acquires several Mission Pharmacal OTCs

BY Michael Johnsen

Mission Pharmacal on Wednesday divested several consumer products to MainPointe Pharmaceuticals along with the marketing rights of additional consumer products that have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewable contract manufacturing agreement to continue manufacturing all of the included products that are currently made in Mission’s manufacturing facility.

“These are exciting agreements that will provide consumers greater access to the products involved due to MainPointe’s existing relationships within more diverse distribution channels,” Neill Walsdorf, Jr., Mission president, said. “Mission remains passionate about the products involved, and more importantly, we are steadfast in our support of the end users who rely on these products every day.”

As part of the agreements, the Thera-Gesic, Thera-Gesic Plus, Dr. Smith’s Diaper Rash Ointment, Dr. Smith’s Diaper Rash Spray, Dr. Smith’s Adult Barrier Spray and Dr. Smith’s Adult Ointment have been divested.

In addition, marketing rights have been licensed by Mission to MainPointe for the following Calcet, Fosfree, Heat Guard, Maxilube and Lycelle Head Lice Removal Kit.

“We look at these agreements as the beginning of an exciting strategic partnership between Mission and MainPointe,” Walsdorf said. “Our industry is continually evolving and we hold strong to the belief that partnering for success is more essential today than ever before.”

The new portfolio of products joins Nexafed and Nexafed Sinus as core MainPointe Pharmaceuticals OTC products being supplied by the manufacturer. This past fall, MainPointe acquired the rights to these popular diversion-resistant cough/cold products from Acura Pharmaceuticals.

 

As part of that deal, MainPointe brought Nexafed 2.0 to market late last year.

“Conversion of pseudoephedrine products into methamphetamine remains an acute problem in many communities,” John Schutte, MainPointe chairman and CEO, said when MainPoint first acquired the rights to market Nexafed.  “The Nexafed products have proven to be a success in curbing this costly problem and we look forward to driving this business forward.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?